Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom

Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021

(2021) Kamal Abu Jabal et al.   Eurosurveillance

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

(2021) Saman Saadat et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Sex differences in the evolution of neutralizing antibodies to SARS-CoV-2

(2021) Ludivine Grzelak et al.   JOURNAL OF INFECTIOUS DISEASES

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

(2021) Maria Prendecki et al.   LANCET

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

(2021) Florian Krammer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes

(2021) Chadi M. Saad-Roy et al.   SCIENCE

Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021

(2021) Sathyavani Subbarao et al.   Eurosurveillance

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

(2021) Joseph E. Ebinger et al.   NATURE MEDICINE

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

(2021) Jamie Lopez Bernal et al.   BMJ-British Medical Journal

Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status

(2021) David W. Eyre et al.   CLINICAL MICROBIOLOGY AND INFECTION

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study

(2021) Madhumita Shrotri et al.   LANCET INFECTIOUS DISEASES

Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom

(2021) Emma Pritchard et al.   NATURE MEDICINE

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

(2020) Mark Ainsworth et al.   LANCET INFECTIOUS DISEASES

A review of vaccine effects on women in light of the COVID-19 pandemic

(2020) Wen-Han Chang   Taiwanese Journal of Obstetrics & Gynecology

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

(2020) Sheila F. Lumley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Convalescent plasma therapy for the treatment of patients with COVID ‐19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels

(2020) Heli Harvala et al.   TRANSFUSION MEDICINE

Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey

(2020) Koen B Pouwels et al.   Lancet Public Health